Reduced risk of recurrent heart attack with anticoagulant drug

November 29, 2001

N.B. Please note that if you are outside North America the embargo for Lancet Press material is 0001 hours UK Time Friday 30th November 2001

Results of a study in this week's issue of THE LANCET show that patients given the anticoagulant drug, bivalirudin, had a reduced risk of recurrent heart attack compared with patients given conventional treatment with heparin.

The combination of anticoagulant therapies (fibrinolytic therapy and the use of unfractionated heparin) for acute heart attack fails to achieve reperfusion (restoration of coronary blood flow) in 40-70% of patients. Harvey White from Green Lane Hospital, Auckland, New Zealand, and colleagues did a randomised trial to compare the thrombin-specific anticoagulant, bivalirudin, with heparin in patients undergoing fibrinolysis with streptokinase for acute heart attack.

Around 17,000 patients from 46 countries, with a specific heart-attack profile (acute ST-elevation myocardial infarction), were randomly assigned an intravenous bolus and 48-hour infusion of either bivalirudin or heparin, together with a standard 1.5 million unit dose of streptokinase (the most commonly used fibrinolytic agent worldwide). The primary endpoint was death within 30 days; secondary endpoints included recurrence of heart attack and bleeding.

Death rates at 30 days were similar in both groups (919 patients (10.8%) in the bivalirudin group and 931 (10.9%) in the heparin group). The risk of recurrent heart attack within four days (reinfarction) was reduced by 30% in the bivalirudin group compared with the heparin group. There was no significant increase in severe bleeding or intracerebral bleeding in patients given bivalirudin.

Harvey White comments: "Thrombin-specific anticoagulation with bivalirudin provides advantages over the use of unfractionated heparin. The clinical benefit/risk relation for bivalirudin versus heparin has shown a reduced risk of reinfarction and suggests a lower risk of the combined outcome of death, non-fatal reinfarction, or non-fatal disabling stroke at the cost of a relatively small increase in moderate bleeding. Bivalirudin should be considered as a new anticoagulant treatment option in patients with acute myocardial infarction treated with streptokinase."
-end-
Contact: Professor Harvey D White, Cardiology Department, Green Lane Hospital, Private Bag 92 189, Auckland 1030, New Zealand; T) +64 9 630 9992; F) +64 9 630 9915; E) harveyw@adhb.govt.nz

Lancet

Related Heart Attack Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Molecular imaging identifies link between heart and kidney inflammation after heart attack
Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction.

Muscle protein abundant in the heart plays key role in blood clotting during heart attack
A prevalent heart protein known as cardiac myosin, which is released into the body when a person suffers a heart attack, can cause blood to thicken or clot--worsening damage to heart tissue, a new study shows.

New target identified for repairing the heart after heart attack
An immune cell is shown for the first time to be involved in creating the scar that repairs the heart after damage.

Heart cells respond to heart attack and increase the chance of survival
The heart of humans and mice does not completely recover after a heart attack.

A simple method to improve heart-attack repair using stem cell-derived heart muscle cells
The heart cannot regenerate muscle after a heart attack, and this can lead to lethal heart failure.

Mount Sinai discovers placental stem cells that can regenerate heart after heart attack
Study identifies new stem cell type that can significantly improve cardiac function.

Fixing a broken heart: Exploring new ways to heal damage after a heart attack
The days immediately following a heart attack are critical for survivors' longevity and long-term healing of tissue.

Heart patch could limit muscle damage in heart attack aftermath
Guided by computer simulations, an international team of researchers has developed an adhesive patch that can provide support for damaged heart tissue, potentially reducing the stretching of heart muscle that's common after a heart attack.

How the heart sends an SOS signal to bone marrow cells after a heart attack
Exosomes are key to the SOS signal that the heart muscle sends out after a heart attack.

Read More: Heart Attack News and Heart Attack Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.